Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Acta Pharmaceutica Sinica B ; (6): 3035-3059, 2021.
Article Dans Anglais | WPRIM | ID: wpr-922741

Résumé

Various boron-containing drugs have been approved for clinical use over the past two decades, and more are currently in clinical trials. The increasing interest in boron-containing compounds is due to their unique binding properties to biological targets; for example, boron substitution can be used to modulate biological activity, pharmacokinetic properties, and drug resistance. In this perspective, we aim to comprehensively review the current status of boron compounds in drug discovery, focusing especially on progress from 2015 to December 2020. We classify these compounds into groups showing anticancer, antibacterial, antiviral, antiparasitic and other activities, and discuss the biological targets associated with each activity, as well as potential future developments.

2.
Chinese Journal of Nosocomiology ; (24)1994.
Article Dans Chinois | WPRIM | ID: wpr-591410

Résumé

OBJECTIVE To investigate the genes associated ?-lactamases in Acinetobacter baumannii(ABA)isolated and preliminary discovery of Acinetobacter-derived cephalosporinases(ADC)-subtype in Shaoxing,Zhejiang.METHODS Eighteen ?-lactamases genes were detected by PCR,and a new ADC ?-lactamases gene fragments produced by PCR were sequenced and analyzed.RESULTS The positive rates of ADC-gene,TEM-gene and OXA-23 group-gene were 85.9%,27.1% and 58.8%,respectively.The other genes were not found in all 85 isolates tested.CONCLUSIONS There are very high positive percentages of ADC,TEM and OXA-23 group genes in A.baumannii isolated clinically and that is the important mechanism of multi-resistance.The ADC gene may be a novel subtype in lactamases(GenBank accession number:EF569590).

SÉLECTION CITATIONS
Détails de la recherche